Press Releases

Scientists at the Fraunhofer Institute for Biomedical Engineering IBMT have been working with international partners to develop a technology platform to help relieve the symptoms of muscle tremors. Tiny biocompatible electrodes in the muscles, combined with external electrodes and controllers, form an intelligent network of sensors and actuators to detect muscle signals and provide electrical stimuli as needed. Together with exoskeletons, the technology could also help people with spinal cord injuries.

They are barely the size of a thumbnail, able to communicate with each other and respond to each other, and designed to make life easier for people with functional limitations. We are talking about a new generation of interactive microimplants developed by the innovation cluster INTAKT, which is funded by the German Federal Ministry of Education and Research (BMBF) and coordinated by the Fraunhofer Institute for Biomedical Engineering IBMT. These miniature assistants can act as a stimulus in cases of tinnitus or digestive tract disorders or help a person’s hand to regain the ability to grip.

Researchers from the Fraunhofer Institute for Biomedical Engineering IBMT have developed the “BioSensoLab“, a mobile biological laboratory with which they can demonstrate new developments to customers and test them together – on site at their companies. These new technologies rely in particular on intelligent sensors combined with artificial intelligence to perform analyses. The lab will be presented at the joint Fraunhofer booth at the MEDICA 2022 trade fair in Düsseldorf from November 14 to 17.

The Fraunhofer Institute for Biomedical Engineering IBMT is contributing its expertise in the field of medical biotechnology and ultrasound to an EC project to work on the next generation of theranostics for brain pathologies using autonomous externally controllable nanonetworks.

The European Partnership for the Assessment of Risks from Chemicals (PARC), launched on 1st of May 2022, will develop a next-generation chemical risk assessment in order to better protect human health and the environment based on a “One Health” approach. It will support the EU’s Chemical Strategy for Sustainability and the European Green Deal’s “zero pollution” ambition. “PARC” is coordinated by the French Agency for Food, Environmental and Occupational Health & Safety (ANSES), and brings together nearly 200 scientific partners from 28 countries as well as 3 EU agencies. “PARC” is funded on an equal basis by Horizon Europe, the 9th EU research and innovation framework programme, and the partnership’s participants with a funding volume of €400 million. The Fraunhofer Institute for Biomedical Engineering IBMT is involved in the project with its expertise in the fields of human biomonitoring, biobanking and toxicology.

In the new EU project “SafePolyMed" an international research team sets out to provide physicians and pharmacists with innovative tools to increase drug treatment safety and educate patients on how to actively manage their own healthcare. The Fraunhofer Institute for Biomedical Engineering IBMT is contributing its many years of expertise in the field of health information systems to the new project.